Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, “Ono”) announces that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc. (Nasdaq: DCPH, CEO: Steven L. Hoerter, “Deciphera”) for US$25.60 per share (total amount of approximately US$2.4 billion) net to the seller in cash, without interest thereon and less any applicable withholding taxes. On June 11, 2024, following the completion of the tender offer, Merger Sub merged with and into Deciphera with Deciphera continuing as the surviving corporation and a wholly owned subsidiary of Ono.
Read the full article: Ono Announces Completion of Acquisition of Deciphera //
Source: https://www.prnewswire.com/news-releases/ono-announces-results-of-tender-offer-to-acquire-deciphera-pharmaceuticals-and-completion-of-acquisition-of-deciphera-a-wholly-owned-subsidiary-of-ono-302169269.html